Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

1

Lebrikizumab demonstrated sustained effectiveness and a favorable safety profile over 52 weeks in adults and adolescents with moderate-to-severe atopic dermatitis.
2

Maintenance dosing every 4 weeks maintained clinical responses in patients with and without head and neck involvement.
3

The study provided long-term real-world data on lebrikizumab, addressing a gap in knowledge for European populations.
4

Lebrikizumab is a monoclonal antibody targeting IL-13, approved for treating severe atopic dermatitis in patients aged 12 and older.
5

The retrospective study involved two referral centers in Northern Italy, evaluating patients treated with lebrikizumab for 52 weeks.

Dermatology And Therapy (Springer)

by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi
March 28, 2026

1